Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…
Invectys at the Third International Symposium on Immunotherapy organised by The Institute for Cancer Vaccines & Immunotherapy (previously known as the Cancer…
J.P. Morgan 35Th Annual Healthcare Conference 2017 San-Francisco…
Medicen Paris Region et Invectys annoncent le succès du projet TelVac pour la recherche d’un candidat vaccin contre le cancer…
With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy Paris,…
Invectys files a patent on the acquisition of antibodies against an immune checkpoint expressed in all types of cancers and strengthens its HLA-G intellectual property…
With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance. Invectys announces fundraising of an additional…
Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine A new clinical hope in cancer…
